Respiratory Syncytial Virus clinical trials at UC Cancer

1 research study open to eligible people

Showing trials for

  • A Study of RV521 in the Treatment of Adult Subjects With an Upper Respiratory Tract Infection

    open to eligible people ages 18-75

    RV521 is to being developed to treat RSV infection and disease in susceptible individuals at high risk for complications. This is an international, multicenter, placebo-controlled study. Eligible subjects are adults with a documented symptomatic RSV infection who have undergone HCT transplantation and are moderately to severely immunocompromised. Qualified subjects will be randomized in a 1:1 ratio to receive RV521 or placebo, twice daily for 10 days.

    at UCLA